Lung cancer trials in Italy

In Italy 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Rozzano
Age
18 years and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00
No phaseTaking people
NUT Project: Nutritional Support in Thoracic Oncology
Where
Peschiera del Garda
Age
18 years and over
People
100
Run by
Casa di Cura Dott. Pederzoli
See details and how to joinNCT07817329
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Florence, Milan, Naples
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Arezzo, Bari, Catania, Meldola, Milan, Modena, Padova, Pisa, Rome
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 2Not yet taking people in Italy
Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
Where
Rozzano
Age
18 years and over
People
30
Run by
Humanitas Mirasole S.p.A.
See details and how to join2025-524125-40-01
Phase 1Taking people
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Where
Naples
Age
18 years and over
People
400 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT04913285
Phase 1/2Not yet taking people in Italy
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Where
Naples, Orbassano
Age
18 years and over
People
171 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00
Phase 2Taking people
A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program
Where
Milan
Age
18 years and over
People
2,000
Run by
Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2024-513660-26-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Aviano, Candiolo, Legnano, Lucca, Milan, Naples, Pesaro, Peschiera del Garda, Rome
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00
Phase 2Not yet taking people in Italy
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
Meldola, Milan, Naples, Negrar, Reggio Emilia
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Milan, Modena, Naples
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
No phaseTaking people
Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer
Where
Milan
People
50
Run by
European Institute of Oncology
See details and how to joinNCT07790406
Phase 3Active, not recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Milan, Monza, Orbassano, Padova, Parma
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Where
Candiolo, Milan, Naples, Rome, Verona
Age
18 years and over
People
594 worldwide
Run by
BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01
Phase 2Not yet taking people in Italy
A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).
Where
Aviano, Bari, Florence, Genoa, Messina, Milan, Modena, Naples, Orbassano, Rome, Rozzano, Taranto, Turin
Age
18 years and over
People
126
Run by
Universita' Degli Studi Di Torino
See details and how to joinNCT03379441 · EU 2024-514701-57-01
Phase 2Taking people
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients
Where
Ancona, Bari, Brindisi, Catania, Civitavecchia, Feltre, Grosseto, Lecco, Macerata, Meldola, Milan, Modena, Monza, Naples, Napoli, Negrar, Orbassano, Palermo, Piacenza, Ponderano, Ravenna, Reggio Emilia, Rionero in Vulture (PZ), Rome, Siracusa, Statte, Teramo, Varese, Verona
Age
18 years and over
People
130
Run by
Fondazione Ricerca Traslazionale
See details and how to join2024-517200-10-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Aviano, Milan, Modena
Age
18 years and over
People
36 worldwide
Run by
Arrivent Biopharma Inc.
See details and how to join2025-522151-26-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Candiolo, Milan, Naples, Roma, Rozzano, Siena
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Milan
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00
Phase 1Not yet taking people in Italy
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Where
Ancona, Meldola, Orbassano, Roma
Age
18 years and over
People
138 worldwide
Run by
Deuteroncology
See details and how to join2023-504897-39-00
Phase 3Active, not recruiting
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Bari, Bergamo, Meldola, Milan, Rome, Verona
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00
No phaseNot yet taking people in Italy
Virtual Reality in Lung Cancer Patients
Where
Olbia
Age
18 months to 80 years
People
60
Run by
Dott.Claudio Sini
See details and how to joinNCT07755501
Phase 2Taking people
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
Where
Avellino, Bari, Florence, Meldola, Messina, Milan, Modena, Monza, Orbassano, Padova, Palermo, Parma, Perugia, Pisa, Ravenna, Reggio Emilia, Rimini, Rome, Saronno, Verona
Age
18 years and over
People
25
Run by
Fondazione Ricerca Traslazionale
See details and how to joinNCT03911193 · EU 2024-518386-95-02
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Bari, Bergamo, Brescia, Catania, Catanzaro, Genoa, Milan, Monza, Naples, Parma, Perugia, Rome, Rozzano, Verona
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 1Taking people
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Where
Milan, Pisa, Verona
Age
18 years and over
People
434 worldwide
Run by
Amgen
See details and how to joinNCT07094113